Background & Aims Liver cirrhosis is the end-stage liver disease associated with poor prognosis. Cardiovascular comorbidity could significantly impact morbidity and mortality of cirrhotic patients. However, little knowledge exists for specific impact of diverse concomitant cardiovascular drugs in cirrhotic patients. Here, we conducted a large, retrospective study to investigate the survival impact of cardiovascular co-medications in patients with liver cirrhosis.
